^
Association details:
| Biomarker: | EGFR exon 19 deletion + PD-L1 expression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small cell lung cancer patients
Published date:
06/13/2022
Excerpt:
We enrolled advanced NSCLC patients who harbored sensitizing EGFR mutation and were treated first-line with osimertinib between 2017 and 2021….In patients with ECOG PS 0 to 1, PD-L1 < 50% and exon 19 deletion had respectively better PFS with an adjusted HR (aHR) of 0.14 (95% CI, 0.04 to 0.50; p = 0.002), an aHR of 0.19 (95% CI, 0.06 to 0.67; p = 0.009) and an aHR of 0.24 (95% CI, 0.10 to 0.57; p = 0.001).
DOI:
https://doi.org/10.1038/s41598-022-13102-7
